人工授精 中国就医指南

Artificial insemination (AI) is a foundational assisted reproductive technology (ART) used in reproductive medicine to address infertility by introducing prepared sperm directly into a woman’s uterus (intrauterine insemination, IUI), cervix (intracervical insemination,ICI), or fallopian tubes (intratubal insemination, ITI). While often colloquially referred to as a 'treatment for infertility,' AI itself is not a disease but a clinical procedure—yet it is universally categorized under reproductive disorders management due to its primary indication: subfertility. Pathogenetically, AI bypasses natural barriers to conception—including cervical mucus hostility, mild male factor infertility (e.g., low sperm count, reduced motility, or abnormal morphology), unexplained infertility, ovulatory dysfunction (when combined with ovulation induction), and certain immunological or anatomical factors (e.g., retroverted uterus or coital difficulties). It does not correct underlying pathology but optimizes the probability of fertilization by concentrating motile sperm and placing them closer to the site of fertilization during the fertile window. Epidemiologically, AI is among the most frequently performed fertility interventions globally; in China, an estimated 15–20% of couples experience infertility, and AI accounts for ~30–40% of all ART cycles initiated annually—particularly in cases of mild male factor or unexplained infertility where IVF is not yet indicated. Key risk factors associated with AI candidacy include advancing female age (>35 years), duration of infertility (>2 years), prior failed timed intercourse or ovulation induction cycles, mild oligoasthenoteratozoospermia (OAT) in male partners, and absence of tubal occlusion or severe endometriosis (which would typically warrant IVF instead). Importantly, AI carries minimal procedural risks—such as mild cramping, spotting, or rare infection—but psychological burden remains substantial: patients often report heightened anxiety, stigma-related distress, marital strain, and diminished sexual spontaneity due to cycle-driven intimacy and repeated treatment expectations. Quality of life impact is further amplified by financial stress, time-intensive monitoring (ultrasounds, hormone assays, clinic visits), and emotional volatility tied to cycle outcomes—especially given per-cycle success rates averaging only 10–20% in optimally selected patients. Cumulative live birth rates after 3–6 well-timed IUI cycles range from 30–50%, underscoring the importance of patient selection, timing precision, and adjunctive hormonal support. As a first-line, minimally invasive intervention, AI serves both diagnostic and therapeutic roles—helping clinicians stratify patients who may require more advanced ART while preserving physiological conception pathways wherever feasible.

# 人工授精（生殖医学科）治疗方案与费用明细

一、非手术/保守治疗方案

适用人群：排卵正常、轻度少弱精、宫颈因素不孕、性交障碍或不明原因不孕者。

• •基础监测+宫腔内人工授精（IUI）：含B超卵泡监测（3–4次）、尿LH检测、精液优化处理、IUI操作

- 单周期费用：3,200–4,800元（含药物促排卵：克罗米芬500–1,200元；来曲唑800–1,500元；HCG触发150–300元）

二、手术/微创介入方案

适用条件：合并中重度男性因素（需睾丸穿刺取精）、宫颈粘连或子宫畸形需宫腔镜预处理者。

• •宫腔镜评估+IUI联合方案：术前检查（白带、传染病、心电图等共980元），宫腔镜检查（2,600元），术后当月IUI

三、特殊复杂情况方案

• •反复IUI失败（≥3周期）：升级为夫精IVF或供精IUI（供精筛查+冻存管理费3,500元），单周期7,800–10,500元
• •免疫性不孕或严重少精症：加用免疫抑制剂（泼尼松片30–60元/月）及抗氧化治疗（左卡尼汀等400–800元/月）

四、方案快速选择指南

• •预算≤4,000元/周期：自然周期IUI（无需促排）
• •追求成功率（35岁以下）：来曲唑促排+IUI（成功率约15%–20%/周期）
• •反复失败或男方精子<5×10⁶/ml：直接转供精IUI或IVF助孕